A 2026 informational release covering what the Leanzene BHB + apple cider vinegar gummy label discloses, where published ingredient research supports category-level claims at studied dosages, how ...
Kevin Richardson, CEO, Telix Precision Medicine, added, “The FDA’s acceptance of our NDA resubmission is an important milestone for Telix. We appreciate the FDA’s constructive engagement and look ...
A 2026 informational report examining Vita Smart Cup Massager's marketing claims, device specifications not disclosed on the product page, cupping and red light research context, return policy fine ...
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for ...
While the financial statements in the Company’s 2025 Annual Report reflect a year focused primarily on corporate restructuring and building the Company’s acquisition platform, management believes the ...
A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company’s website at https://ir.lbpharma.us/investors/events/, where a replay of the ...
Dental Care of Stamford, a trusted dental practice serving Fairfield County, has published a comprehensive patient resource addressing one of the most persistent challenges in cosmetic dentistry: not ...
About NARCAN® Nasal Spray NARCAN ® Nasal Spray is a pure opioid antagonist indicated for emergency use to reverse known or suspected opioid overdose, as manifested by respiratory and/or severe central ...
A veteran architect of Gemini’s Asia Pacific expansion, Ms. Gani joins to lead institutional buildout as Solana Company executes on its strategy to drive yield expansion, enhance revenue generation, ...
About PROCEPT BioRobotics Corporation PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics ...
EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...
We are delighted to be a part of an initiative like The Gateway, a highly curated environment of thought leaders in the healthcare industry,” said ClinNEXUS CEO and Gateway speaker, Greg Carroll, M.D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results